<SEC-DOCUMENT>0001615774-17-002265.txt : 20170511
<SEC-HEADER>0001615774-17-002265.hdr.sgml : 20170511
<ACCEPTANCE-DATETIME>20170511171535
ACCESSION NUMBER:		0001615774-17-002265
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20170510
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
ITEM INFORMATION:		Submission of Matters to a Vote of Security Holders
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20170511
DATE AS OF CHANGE:		20170511

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ATOSSA GENETICS INC
		CENTRAL INDEX KEY:			0001488039
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				264753208
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35610
		FILM NUMBER:		17835429

	BUSINESS ADDRESS:	
		STREET 1:		107 SPRING STREET
		CITY:			SEATTLE
		STATE:			WA
		ZIP:			98104
		BUSINESS PHONE:		206.588.0256

	MAIL ADDRESS:	
		STREET 1:		107 SPRING STREET
		CITY:			SEATTLE
		STATE:			WA
		ZIP:			98104
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>s106153_8k.htm
<DESCRIPTION>8-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES SECURITIES AND EXCHANGE
COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>WASHINGTON, D.C. 20549</B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM 8-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CURRENT REPORT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Pursuant to Section&nbsp;13 or 15(d)
of the Securities Exchange Act of 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Date of Report (Date of Earliest Event
Reported): May 10, 2017</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 24pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Atossa Genetics Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of registrant as specified in
its charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR>
    <TD STYLE="vertical-align: top; text-align: center; border-bottom: Black 1pt solid; width: 32%"><FONT STYLE="font-size: 10pt">Delaware </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-bottom: 1pt; width: 2%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center; border-bottom: Black 1pt solid; width: 32%"><FONT STYLE="font-size: 10pt">001-35610 </FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-bottom: 1pt; width: 2%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center; border-bottom: Black 1pt solid; width: 32%"><FONT STYLE="font-size: 10pt">26-4753208</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">(State or other jurisdiction of </FONT><BR>
<FONT STYLE="font-size: 10pt">incorporation) </FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">(Commission File Number) </FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">(I.R.S. Employer</FONT><BR>
<FONT STYLE="font-size: 10pt">Identification No.)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR>
    <TD STYLE="vertical-align: top; border-bottom: Black 1pt solid; width: 49%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">107 Spring Street</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Seattle, Washington</P></TD>
    <TD STYLE="vertical-align: bottom; padding-bottom: 1pt; width: 2%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; border-bottom: Black 1pt solid; width: 49%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">98104</P></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">(Address of principal executive offices) </FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">(Zip Code)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Registrant&rsquo;s telephone number, including
area code: (206)&nbsp;325-6086</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>Not Applicable</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Former name or former address, if changed
since last report</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&uml;</FONT></TD><TD STYLE="text-align: justify">Written communications pursuant to Rule&nbsp;425 under
the Securities Act (17 CFR 230.425)</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&uml;</FONT></TD><TD STYLE="text-align: justify">Soliciting material pursuant to Rule&nbsp;14a-12 under
the Exchange Act (17 CFR 240.14a-12)</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&uml;</FONT></TD><TD STYLE="text-align: justify">Pre-commencement communications pursuant to Rule&nbsp;14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&uml;</FONT></TD><TD STYLE="text-align: justify">Pre-commencement communications pursuant to Rule&nbsp;13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c))</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item&nbsp;2.02. Results of Operations and Financial Condition.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On May 11, 2017, Atossa Genetics Inc. (the &ldquo;Company&rdquo;)
issued a press release announcing first quarter 2017 financial results and a company update. A copy of the press release is attached
as Exhibit 99.1 to this current report and is incorporated herein by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 3.01 Notice of Delisting or Failure to Satisfy a Continued
Listing Rule or Standard; Transfer of Listing.&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">On May 11, 2017, the Company received a letter from NASDAQ that
the Company was not in compliance with NASDAQ Listing Rule 5550(a)(2) &ndash; bid price, because the Company's common stock failed
to maintain a minimum closing bid price of $1.00 per share for 30 consecutive business days. The Company has until November 7,
2017 to regain compliance. In the event the Company does not regain compliance by then, the Company may be eligible for additional
time if at that time it meets the continued listing requirement for market value of publicly held shares and all other initial
listing standards, with the exception of the bid price requirement, and provides written notice to NASDAQ of its intention to cure
the deficiency during the second compliance period, including by effecting a reverse stock split, if necessary. The letter also
states that the NASDAQ staff will provide written notification that the Company has regained compliance if the bid price of the
Company's common stock closes at $1.00 per share or more for a minimum of 10 consecutive business days.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The NASDAQ notice has no immediate effect on the listing or trading
of the Company&rsquo;s common stock on the NASDAQ Stock Market. The Company intends to actively monitor the bid price for its common
stock between now and November 7, 2017, and will consider available options to resolve the deficiency and regain compliance with
the minimum bid price requirement.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item&nbsp;5.07.&nbsp;Submission of Matters to a Vote of Security
Holders</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On May 9, 2017, the Company held its 2017 Annual Meeting of
Stockholders (the &ldquo;Annual Meeting&rdquo;). The following items of business were considered and voted upon at the Annual Meeting:
(1) the election of two Class II directors named in the proxy statement; (2) the ratification of the selection of BDO USA LLP as
our independent registered public accounting firm for the fiscal year ending December 31, 2017; (3) the approval to increase authorized
shares under Atossa Genetics 2010 Stock Option and Incentive Plan by 1,500,000 shares; and (4) the transaction of any other business
that may properly come before the meeting or any adjournment thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The number of shares of common stock entitled to vote at the
Annual Meeting was 6,008,913. The number of shares of common stock present or represented by valid proxy at the annual meeting
was 3,133,002. All proposals passed. The number of votes cast for and against, and the number of abstentions and broker non-votes
with respect to the matters voted upon at the Annual Meeting are set forth below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-size: 10pt"><I>(i)</I></FONT></TD>
    <TD><FONT STYLE="font-size: 10pt"><I>Election of two Class&nbsp;II Directors</I></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The stockholders elected two Class II directors as set forth
below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="border-bottom: Black 1pt solid">Nominee</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="border-bottom: Black 1pt solid">Votes For</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="border-bottom: Black 1pt solid">Votes Withheld</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="border-bottom: Black 1pt solid">Broker Non-Votes</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 31%; text-align: left">Dr. Stephen Galli</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 20%; text-align: right">1,298,422</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 20%; text-align: right">0</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 20%; text-align: right">1,834,580</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Richard Steinhart</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,283,042</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">15,380</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,834,580</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px"><FONT STYLE="font-size: 10pt"><I>(ii)</I></FONT></TD>
    <TD><FONT STYLE="font-size: 10pt"><I>Ratification of Auditors</I></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The stockholders ratified the appointment of BDO USA LLP as
the Company&rsquo;s independent registered public accounting firm for the fiscal year ending December 31, 2017 as set forth below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">Votes For</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">Votes Against</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">Abstain</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">Broker Non-Votes</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 23%; text-align: right">3,094,484</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 22%; text-align: right">17,837</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 22%; text-align: right">20,681</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 22%; text-align: right">0</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px"><FONT STYLE="font-size: 10pt"><I>(iii)</I></FONT></TD>
    <TD><FONT STYLE="font-size: 10pt"><I>Increase Authorized Shares under Option Plan</I></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The stockholders approved an increase of 1,500,000 shares to
the option plan as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">Votes For</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">Votes Against</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">Abstain</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">Broker Non-Votes</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 23%; text-align: right">857,839</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 22%; text-align: right">432,020</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 22%; text-align: right">8,563</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 22%; text-align: right">1,834,580</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>The information in the report, including Exhibit 99.1 attached
hereto, shall not be deemed to be &ldquo;filed&rdquo; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended,
or otherwise subject to the liabilities of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended.
The information contained herein and in the accompanying exhibit shall not be incorporated by reference into any filing with the
U.S. Securities and Exchange Commission made by the Company, whether made before or after the date hereof, regardless of any general
incorporation language in such filing.</I><BR>
<I>&nbsp; <B>&nbsp;</B></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item&nbsp;9.01. Financial Statements and Exhibits.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(d)&nbsp;Exhibits</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="border-bottom: black 1pt solid; width: 12%"><FONT STYLE="font-size: 10pt">Exhibit No.</FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD NOWRAP STYLE="border-bottom: black 1pt solid; width: 86%"><FONT STYLE="font-size: 10pt">Description</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">99.1 </FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">Press Release, dated May 11, 2017</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">* * *</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;&nbsp;</P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">Date: May 11, 2017</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">Atossa Genetics Inc.&nbsp;</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 5%"><FONT STYLE="font-size: 10pt">By:&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; width: 30%"><FONT STYLE="font-size: 10pt">/s/ Kyle Guse&nbsp;</FONT></TD>
    <TD STYLE="width: 15%">&nbsp;</TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Kyle Guse</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Chief Financial Officer, General Counsel and Secretary&nbsp;</FONT></TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Exhibit&nbsp;Index</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="border-bottom: black 1pt solid; width: 12%"><FONT STYLE="font-size: 10pt">Exhibit No.</FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD NOWRAP STYLE="border-bottom: black 1pt solid; width: 86%"><FONT STYLE="font-size: 10pt">Description</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">99.1 </FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><A HREF="s106153_ex99-1.htm"><FONT STYLE="font-size: 10pt">Press Release, dated May 11, 2017</FONT></A></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 5; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>s106153_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B><IMG SRC="logo_ex99-1.jpg" ALT="" STYLE="width: 272px; height: 107px"></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Atossa Genetics Announces First Quarter
2017 Financial Results </B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>and Provides Company Update</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>SEATTLE, May 11, 2017</B> &mdash; Atossa Genetics Inc. (NASDAQ:
ATOS) today announced First Quarter ended March 31, 2017 financial results and provided an update on recent company developments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Steve Quay, President and CEO, commented, &ldquo;We are encouraged
by our positive progress in advancing the endoxifen program with our ongoing Phase 1 endoxifen study and pleased that our fulvestrant
microcatheter study is proceeding at Montefiore Medical Center. We look forward to completing our endoxifen Phase 1 study in the
next quarter and commencing a Phase 2 study in the second half of 2017.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Recent Corporate Developments&#9;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">Atossa&rsquo;s important recent
developments include the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">May 2017 &ndash; Atossa received second positive safety decision in
Phase 1 topical endoxifen study.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">May 2017 &ndash; Institutional Review Board approved continuation
of fulvestrant microcatheter Phase 2 study at Montefiore Medical Center.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">April 2017 - Atossa received positive interim review from independent
safety committee in Phase 1 topical endoxifen study.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">April 2017 - Atossa enrolled first cohort of eight subjects in endoxifen
study.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">March 2017 &ndash; Atossa raised approximately $4.4 million in gross
proceeds in a public offering. </FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">March 2017 - Atossa opened its endoxifen Phase 1 clinical study. </FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Atossa plans to commence a Phase 2 clinical study of endoxifen in
the second half of 2017. </FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Q1 2017 Financial Results </B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We are in the research and development phase and do not generate
revenue.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Operating expenses: Total operating expenses were approximately
$1.7 million for the three months ended March 31, 2017, consisting of general and administrative (G&amp;A) expenses of approximately
$1.1 million and R&amp;D expenses of approximately $544,000. Operating expenses for the three months ended March 31, 2017 decreased
approximately $641,000, or 27.5%, from approximately $2.3 million for the three months ended March 31, 2016, which consisted of
G&amp;A expenses of approximately $2.2 million, and R&amp;D expenses of approximately $150,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company recorded a net loss of $1.7 million, for the three
months ended March 31, 2017, as compared to a net loss of $2.3 million for the three months ended March 31, 2016.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About Atossa Genetics</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Atossa Genetics Inc., is a clinical-stage pharmaceutical company
developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions. For more information, please
visit www.atossagenetics.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Forward-Looking Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Forward-looking statements in this press release, which Atossa
undertakes no obligation to update, are subject to risks and uncertainties that may cause actual results to differ materially from
the anticipated or estimated future results, including the risks and uncertainties associated with actions and inactions by the
FDA, the outcome or timing of regulatory approvals needed by Atossa, lower than anticipated rate of patient enrollment, results
of clinical studies, the safety and efficacy of Atossa's products and services, performance of clinical research organizations
and investigators, obstacles resulting from proprietary rights held by others, such as patent rights, and other risks detailed
from time to time in Atossa's filings with the Securities and Exchange Commission, including without limitation its periodic reports
on Form 10-K and 10-Q, each as amended and supplemented from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Atossa Genetics Company Contact:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Atossa Genetics Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Kyle Guse</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">CFO and General Counsel</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(O) 800-351-3902</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">kyle.guse@atossagenetics.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Investor Relations Contact</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Scott Gordon</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">CorProminence LLC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">377 Oak Street</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Concourse 2</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Garden City, NY 11530</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Office: 516.222.2560</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">scottg@corprominence.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Source: Atossa Genetics Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ATOSSA GENETICS INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CONDENSED CONSOLIDATED BALANCE SHEETS
(UNAUDITED)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center">March 31,</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center">December&nbsp;31,</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2017</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-decoration: underline; text-align: center">Assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Current assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 70%; text-align: left; padding-left: 0.25in">Cash and cash equivalents</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">1,167,011</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">3,027,962</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.25in">Restricted cash</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">55,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">55,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 0.25in">Prepaid expense</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">294,831</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">171,601</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.25in">Total current assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,516,842</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,254,563</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.25in">Furniture and equipment, net</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">27,761</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">55,119</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.25in">Intangible assets, net</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">610,013</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">640,440</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 0.25in">Other assets</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">148,566</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">194,250</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; padding-left: 0.25in">Total assets</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">2,303,182</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">4,144,372</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-decoration: underline; text-align: left; padding-left: 9pt">Liabilities and Stockholders&rsquo; Equity</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">Current liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">&nbsp;&nbsp;&nbsp;&nbsp;Accounts payable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">386,877</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">254,320</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.25in">Accrued expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">34,610</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">16,964</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.25in">Payroll liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">330,889</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">769,899</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 0.25in">Other current liabilities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">22,401</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">6,083</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 0.25in">Total current liabilities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">774,777</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,047,266</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Commitments and contingencies</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Stockholders&rsquo; equity</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 0.25in">Preferred stock - $.001 par value; 10,000,000 shares authorized, 0&nbsp;shares issued and outstanding</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 0.25in">Common stock - $.015 par value; 75,000,000 shares
    authorized, 3,786,913&nbsp;shares &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;is issued and outstanding</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">56,804</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">56,804</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">Additional paid-in capital</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">60,478,903</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">60,344,050</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 9pt">Accumulated deficit</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(59,007,302</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(57,303,748</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 9pt">Total stockholders&rsquo; equity</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,528,405</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">3,097,106</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: 9pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Total liabilities and stockholders&rsquo; equity</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">2,303,182</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">4,144,372</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;&nbsp;</P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ATOSSA GENETICS INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CONDENSED CONSOLIDATED STATEMENTS OF
OPERATIONS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(UNAUDITED)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">For&nbsp;the&nbsp;Three&nbsp;Months&nbsp;Ended<BR> March 31,</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2017</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Operating expenses:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 70%; text-align: left; text-indent: 9pt">Research and development</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">544,302</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">149,971</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: 9pt">General and administrative</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,142,544</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2,177,569</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 0.25in">Total operating expenses</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,686,846</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2,327,540</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Operating loss</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,686,846</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,327,540</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Other expense, net</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(16,708</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Loss before income taxes</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,703,554</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,327,540</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Income taxes</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;&nbsp;&nbsp;&nbsp;Loss from operations</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(1,703,554</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(2,327,540</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Net loss</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(1,703,554</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(2,327,540</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Loss per common share - basic and diluted</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(0.45</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(0.98</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt">Weighted average shares outstanding, basic and diluted</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">3,786,913</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">2,382,757</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>





</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>logo_ex99-1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 logo_ex99-1.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "  4<# 2(  A$! Q$!_\0
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M&M2G;X4=G114<]Q#:P//<2I%$@RSNV ![F@P)**X6]^*NAPW!M["&[U&4?\
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M"2?4FOG[Q[_R/6L?]?!_D*Z+P8/'MQ!_9NERSVMB#@RSIA8O7:2,_@*H>-O
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M)Y:OM+ '!/./I64?B+X4!P=63/IY;_X4 HM[(ZBBL71_%>CZ_>36NF71G>%
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M57F]UXS\.1>'+">,?:]4LH5-M%Y3@K+LV\\=/6N_T^2>73K:2Z"BX>)6D"C
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<*ZC3M%L-*:5[2W"RS',LK$L\A]V/)HH"3N?_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
